Study: EVIS: Early Vasopressors in Sepsis (EudraCT Ne: 2021-006886-39) EVIS Participant No.; Insert Patient ID/Addressograph label This patient has been randomised to the USUAL/STANDARD CARE arm of the EVIS study. Insert Patient ID/Addressograph label Participant randomised on: 	EVIS: Information Sheet for Clinical Staff: CONTROL Arm $=$			
Participant No.: Intern Patient ID/Addressograph label Randomisation: Intern Patient ID/Addressograph label Participant randomised on: (insert time hh:mm) Participant randomised on: (insert time hh:mm) If you need more information: (insert time hh:mm) If tracting time head Care (Control) arm (insert time hh:mm) If tracting time time research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids arbelow. Initial treatment (3 hours post-random	Study:	EVIS: Early Vasopressors in Sepsis	(EudraCT No: 2021-006886-39)	
This patient has been randomised to the USUAL/STANDARD CARE arm of the EVIS study. Participant randomised on: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) Important: Only trained research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with permitted balanced crystalloid IV fluids and thereahold. Initial treatment (3 hours post-randomisation) • Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. • Titrate intravenous fluid administration to target MAP > 65 mmHg. • Den	-			
This patient has been randomised to the USUAL/STANDARD CARE arm of the EVIS study. Participant randomised on: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) If you need more information: (insert date) at(insert time hh:mm) Important: Only trained research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with permitted balanced crystalloid IV fluids and thereahold. Initial treatment (3 hours post-randomisation) • Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. • Titrate intravenous fluid administration to target MAP > 65 mmHg. • Den	Randomisation:		Insert Patient ID/Addressograph label	
	This patient has be			
 Contact the Research Team on				
 The protocol and other current study documents can be found on the website www.evis.scot.nhs.uk or by scanning the QRS code opposite Key information for CLINICIANS for STANDARD CARE (CONTROL) arm Randomisation: Standard Care (Control) arm Study treatment period: maximum 48 hours from time of randomisation. See above. IMPORTANT: Only trained research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with permitted balanced crystalloid IV fluids (any brand) Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) Compound Sodium Lactate Solution for Infusion (Ringers Lactate or Hartmanns solution). Plasma-Lyte 148 Solution for Infusion Anticipated most participants will receive up to approximately 30ml/kg in the first 3 hours using 250-1000ml rapid infusion (bolus) of the permitted balanced crystalloids for fluid resuscitation. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not neceive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids:	If you need more information:			
 Randomisation: Standard Care (Control) arm Study treatment period: maximum 48 hours from time of randomisation. See above. IMPORTANT: Only trained research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids as below. Initial treatment (3 hours post-randomisation) Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) 	The protocol and other current study documents can be found on the website www.evis.scot.nhs.uk or by scanning the QRS code opposite			
 Study treatment period: maximum 48 hours from time of randomisation. See above. IMPORTANT: Only trained research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids (any brand) Fluid resuscitation: Administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) Compound Sodium Lactate Solution for Infusion (Ringers Lactate or Hartmanns solution) Plasma-Lyte 148 Solution for Infusion Anticipated most participants will receive up to approximately 30ml/kg in the first 3 hours using 250-1000ml rapid infusion (bolus) of the permitted balanced crystalloids for fluid resuscitation. Ongoing treatment (up to 45 hours post-randomisation) Further balanced crystalloid boluses for resuscitation is at discretion of clinical team. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of <125ml/hour Requirement for operative inte	Key information for CLINICIANS for STANDARD CARE (CONTROL) arm			
 IMPORTANT: Only trained research staff on the site delegation log can initiate study treatment with permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids as below. Initial treatment (3 hours post-randomisation) Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) 	Randomisation: Standard Care (Control) arm			
 permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment with balanced crystalloid IV fluids as below. Initial treatment (3 hours post-randomisation) Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) 	Study treatment period: maximum 48 hours from time of randomisation. See above.			
 Fluid resuscitation: Administer balanced crystalloid intravenous fluid via PERIPHERAL venous cannula. Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) Compound Sodium Lactate Solution for Infusion (Ringers Lactate or Hartmanns solution) Plasma-Lyte 148 Solution for Infusion Anticipated most participants will receive up to approximately 30ml/kg in the first 3 hours using 250-1000ml rapid infusion (bolus) of the permitted balanced crystalloids for fluid resuscitation. Ongoing treatment (up to 45 hours post-randomisation) Further balanced crystalloid boluses for resuscitation is at discretion of clinical team. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician must not receive any peripheral vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor of clinician at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where perisole is completed. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed.	permitted balanced crystalloid IV fluids. Thereafter, treating clinicians should continue study treatment			
 cannula. Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) Compound Sodium Lactate Solution for Infusion (Ringers Lactate or Hartmanns solution) Plasma-Lyte 148 Solution for Infusion Anticipated most participants will receive up to approximately 30ml/kg in the first 3 hours using 250-1000ml rapid infusion (bolus) of the permitted balanced crystalloids for fluid resuscitation. Ongoing treatment (up to 45 hours post-randomisation) Further balanced crystalloid boluses for resuscitation is at discretion of clinical team. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where possible Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 	Initial treatment (3 hours post-randomisation)			
 Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) Compound Sodium Lactate Solution for Infusion (Ringers Lactate or Hartmanns solution) Plasma-Lyte 148 Solution for Infusion Anticipated most participants will receive up to approximately 30ml/kg in the first 3 hours using 250-1000ml rapid infusion (bolus) of the permitted balanced crystalloids for fluid resuscitation. Ongoing treatment (up to 45 hours post-randomisation) Further balanced crystalloid boluses for resuscitation is at discretion of clinical team. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where possible Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 				
 1000ml rapid infusion (bolus) of the permitted balanced crystalloids for fluid resuscitation. Ongoing treatment (up to 45 hours post-randomisation) Further balanced crystalloid boluses for resuscitation is at discretion of clinical team. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where possible Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 	 Titrate intravenous fluid administration to target MAP > 65 mmHg. Permitted balanced crystalloid IV fluids (any brand) Compound Sodium Lactate Solution for Infusion (Ringers Lactate or Hartmanns solution) 			
 Further balanced crystalloid boluses for resuscitation is at discretion of clinical team. Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where possible Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 				
 Titrate intravenous fluid administration to target MAP > 65 mmHg. Maintenance and rescue treatment that may be prescribed by the treating clinician Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where possible Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 	Ongoing treatment (up to 45 hours post-randomisation)			
 Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour Requirement for operative intervention: Maintain treatment allocation where possible Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 				
 Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 	 Rescue vasopressors: Rescue vasopressor of clinician choice via CENTRAL line. Participants must not receive any peripheral vasopressor infusion during the 48 hour study period even where peripheral administration is accepted practice at site. Maintenance intravenous fluids: Defined as any fluid at a rate of ≤125ml/hour 			
Other treatment: As per UK national guidelines/local protocols on sepsis.	 Anaesthetist discretion permitted for other fluids, blood product and vasopressor use. End of study period (> 48 hours since randomisation): Treatment may continue as per standard care once the EVIS study period is completed. 			
	Other treatment:	As per UK national guidelines/local protoco	ls on sepsis.	